CCR3 inhibition for ocular angiogenesis and macular degeneration
View Patent ↗Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
1. A method of treating choroidal neovascularization or wet macular degeneration, comprising administering an effective amount of a CCR3-specific binding molecule to a patient having choroidal neovascularization or wet macular degeneration wherein the specific binding molecule is a small organic molecule.
2. The method of claim 1 wherein the CCR3-specific binding molecule is orally administered to the patient.
3. The method of claim 1 wherein the CCR3-specific binding molecule is intravenously administered to the patient.
4. The method of claim 1 wherein the CCR3-specific binding molecule is intraocularly injected into the patient.
5. The method of claim 1 wherein the CCR3-specific binding molecule is topically administered to the patient via eye drops.
6. The method of claim 1 wherein the CCR3-specific binding molecule is an organic molecule with a molecular weight less than 2000.
7. The method of claim 1 wherein the CCR3-specific binding molecule is an organic molecule with a molecular weight less than 1000.
8. The method of claim 1 wherein the CCR3-specific binding molecule is an organic molecule with a molecular weight less than 500.
9. The method of claim 1 wherein the CCR3-specific binding molecule is (S)-methyl-2-naphthoylamino-3-(4-nitrophenyl)propionate.